Britta C. Martel

Ballerup, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Non-Invasive Biomarker Models for Objective Severity Assessment and Detection of Subclinical Inflammation in Non-Lesional Atopic Dermatitis.

Non-Invasive Biomarker Models for Objective Severity Assessment and Detection of Subclinical Inflammation in Non-Lesional Atopic Dermatitis.

Journal: The British journal of dermatology

Published: May 26, 2026

Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results.

Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results.

Journal: The Journal of allergy and clinical immunology

Published: April 29, 2025

Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials.

Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials.

Journal: American journal of clinical dermatology

Published: March 07, 2025

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.

Journal: American journal of clinical dermatology

Published: December 02, 2024

Neutralizing IL-22RA1 improves histologic and molecular alterations associated with atopic dermatitis pathogenesis.

Neutralizing IL-22RA1 improves histologic and molecular alterations associated with atopic dermatitis pathogenesis.

Journal: The Journal of allergy and clinical immunology

Published: October 21, 2024

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.

Journal: Allergy

Published: September 06, 2023

Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity.

Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity.

Journal: PloS one

Published: August 31, 2022

Translational Animal Models of Atopic Dermatitis for Preclinical Studies.

Translational Animal Models of Atopic Dermatitis for Preclinical Studies.

Journal: The Yale journal of biology and medicine

Published: September 29, 2017

Hypochlorous acid is antipruritic and anti-inflammatory in a mouse model of atopic dermatitis.

Hypochlorous acid is antipruritic and anti-inflammatory in a mouse model of atopic dermatitis.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: June 02, 2017

The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses.

The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses.

Journal: Allergy

Published: January 14, 2017

Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis.

Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis.

Journal: Experimental dermatology

Published: January 29, 2016

Different cytokine profiles of skin-derived T cell cultures from patients with atopic dermatitis and psoriasis.

Different cytokine profiles of skin-derived T cell cultures from patients with atopic dermatitis and psoriasis.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: October 14, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026